Shares of AbbVie Inc. ABBV inched 0.99% higher to $181.22 Friday, on what proved to be an all-around favorable trading ...

Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

ABBV-291 is under development for the treatment of relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and ...

So if you can make peace with those two factors, AbbVie's stock is worth buying today. Just remember that it's the most ...

Old Port Advisors lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.7% in the 4th quarter, ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $179.44 which represents a slight increase of $1.74 or 0.98% from the prior close of $177.7. The stock opened at $178.66 and touched a ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

AbbVie (NYSE: ABBV ) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings ...

GAMMA Investing LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 9.5% during the fourth quarter, ...